New Zealand's drug development industry

Michelle Marie Lockhart, Zaheer Ud Din Babar, Christopher Carswell, Sanjay Garg

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The pharmaceutical industry's profitability depends on identifying and successfully developing new drug candidates while trying to contain the increasing costs of drug development. It is actively searching for new sources of innovative compounds and for mechanisms to reduce the enormous costs of developing new drug candidates. There is an opportunity for academia to further develop as a source of drug discovery. The rising levels of industry outsourcing also provide prospects for organisations that can reduce the costs of drug development. We explored the potential returns to New Zealand (NZ) from its drug discovery expertise by assuming a drug development candidate is out-licensed without clinical data and has anticipated peak global sales of $350 million. We also estimated the revenue from NZ's clinical research industry based on a standard per participant payment to study sites and the number of industry-sponsored clinical trials approved each year. Our analyses found that NZ's clinical research industry has generated increasing foreign revenue and appropriate policy support could ensure that this continues to grow. In addition the probability-based revenue from the out-licensing of a drug development candidate could be important for NZ if provided with appropriate policy and financial support.

Original languageEnglish
Pages (from-to)4339-4351
Number of pages13
JournalInternational Journal of Environmental Research and Public Health
Volume10
Issue number9
DOIs
Publication statusPublished - 13 Sep 2013
Externally publishedYes

Fingerprint

Drug Industry
New Zealand
Industry
Drug Costs
Drug Discovery
Pharmaceutical Preparations
Outsourced Services
Financial Support
Licensure
Research
Clinical Trials
Organizations
Costs and Cost Analysis

Cite this

Lockhart, Michelle Marie ; Babar, Zaheer Ud Din ; Carswell, Christopher ; Garg, Sanjay. / New Zealand's drug development industry. In: International Journal of Environmental Research and Public Health. 2013 ; Vol. 10, No. 9. pp. 4339-4351.
@article{6ee76ebd0bef4a76a8346773b23c233f,
title = "New Zealand's drug development industry",
abstract = "The pharmaceutical industry's profitability depends on identifying and successfully developing new drug candidates while trying to contain the increasing costs of drug development. It is actively searching for new sources of innovative compounds and for mechanisms to reduce the enormous costs of developing new drug candidates. There is an opportunity for academia to further develop as a source of drug discovery. The rising levels of industry outsourcing also provide prospects for organisations that can reduce the costs of drug development. We explored the potential returns to New Zealand (NZ) from its drug discovery expertise by assuming a drug development candidate is out-licensed without clinical data and has anticipated peak global sales of $350 million. We also estimated the revenue from NZ's clinical research industry based on a standard per participant payment to study sites and the number of industry-sponsored clinical trials approved each year. Our analyses found that NZ's clinical research industry has generated increasing foreign revenue and appropriate policy support could ensure that this continues to grow. In addition the probability-based revenue from the out-licensing of a drug development candidate could be important for NZ if provided with appropriate policy and financial support.",
keywords = "Clinical research, Drug development, Drug discovery, Economic benefits, New Zealand",
author = "Lockhart, {Michelle Marie} and Babar, {Zaheer Ud Din} and Christopher Carswell and Sanjay Garg",
year = "2013",
month = "9",
day = "13",
doi = "10.3390/ijerph10094339",
language = "English",
volume = "10",
pages = "4339--4351",
journal = "International Journal of Environmental Research and Public Health",
issn = "1661-7827",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "9",

}

New Zealand's drug development industry. / Lockhart, Michelle Marie; Babar, Zaheer Ud Din; Carswell, Christopher; Garg, Sanjay.

In: International Journal of Environmental Research and Public Health, Vol. 10, No. 9, 13.09.2013, p. 4339-4351.

Research output: Contribution to journalArticle

TY - JOUR

T1 - New Zealand's drug development industry

AU - Lockhart, Michelle Marie

AU - Babar, Zaheer Ud Din

AU - Carswell, Christopher

AU - Garg, Sanjay

PY - 2013/9/13

Y1 - 2013/9/13

N2 - The pharmaceutical industry's profitability depends on identifying and successfully developing new drug candidates while trying to contain the increasing costs of drug development. It is actively searching for new sources of innovative compounds and for mechanisms to reduce the enormous costs of developing new drug candidates. There is an opportunity for academia to further develop as a source of drug discovery. The rising levels of industry outsourcing also provide prospects for organisations that can reduce the costs of drug development. We explored the potential returns to New Zealand (NZ) from its drug discovery expertise by assuming a drug development candidate is out-licensed without clinical data and has anticipated peak global sales of $350 million. We also estimated the revenue from NZ's clinical research industry based on a standard per participant payment to study sites and the number of industry-sponsored clinical trials approved each year. Our analyses found that NZ's clinical research industry has generated increasing foreign revenue and appropriate policy support could ensure that this continues to grow. In addition the probability-based revenue from the out-licensing of a drug development candidate could be important for NZ if provided with appropriate policy and financial support.

AB - The pharmaceutical industry's profitability depends on identifying and successfully developing new drug candidates while trying to contain the increasing costs of drug development. It is actively searching for new sources of innovative compounds and for mechanisms to reduce the enormous costs of developing new drug candidates. There is an opportunity for academia to further develop as a source of drug discovery. The rising levels of industry outsourcing also provide prospects for organisations that can reduce the costs of drug development. We explored the potential returns to New Zealand (NZ) from its drug discovery expertise by assuming a drug development candidate is out-licensed without clinical data and has anticipated peak global sales of $350 million. We also estimated the revenue from NZ's clinical research industry based on a standard per participant payment to study sites and the number of industry-sponsored clinical trials approved each year. Our analyses found that NZ's clinical research industry has generated increasing foreign revenue and appropriate policy support could ensure that this continues to grow. In addition the probability-based revenue from the out-licensing of a drug development candidate could be important for NZ if provided with appropriate policy and financial support.

KW - Clinical research

KW - Drug development

KW - Drug discovery

KW - Economic benefits

KW - New Zealand

UR - http://www.scopus.com/inward/record.url?scp=84884683459&partnerID=8YFLogxK

U2 - 10.3390/ijerph10094339

DO - 10.3390/ijerph10094339

M3 - Article

VL - 10

SP - 4339

EP - 4351

JO - International Journal of Environmental Research and Public Health

JF - International Journal of Environmental Research and Public Health

SN - 1661-7827

IS - 9

ER -